 |
| |
Please click here if you wish to skip directly to your Table of Contents listing the most recent Abstract Database additions.
Please click here if you wish to skip directly to the Table of Contents below. To learn more about our MedIntelliBase Custom Email Alerts, click here to complete our request form or contact us directly. Please click here to learn how to use this alert. |
|
(A small sampling of results from a September 17 to October 16,
2006 MIB Abstract Alert search) |
|
Go to Archive |
AngioDynamics to Present at UBS 2006 Global Life Sciences Investor Conference
Business Wire. New York: Sep 20, 2006. pg. 1
Queensbury, N.Y.
AngioDynamics, Inc. Joe Gerardi, 800-772-6446 x115 www.AngioDynamics.com or Lippert/Heilshorn & Associates, Inc. (Investor Relations) Kim Sutton Golodetz, 212-838-3777 kgolodetz@lhai.com Bruce Voss, 310-691-7100 bvoss@lhai.com
AngioDynamics, Inc. (NASDAQ:ANGO) announced that Joseph G. Gerardi, AngioDynamics' chief financial officer, will present at the UBS 2006 Global Life Sciences Conference on Wednesday, September 27, 2006, at 2:00 PM Eastern Time. The conference will be held at the Grand Hyatt Hotel in New York City from September 25 through September 28, 2006.
Individuals may listen to a live web cast of the presentation by logging on to the Investor Relations section of AngioDynamics' web site www.angiodynamics.com a few minutes prior to start time to download any necessary software.
The UBS Global Life Sciences Conference will feature representatives from over 350 companies from the following major life sciences sectors: biotechnology, life sciences (genomics and tools), medical technology, pharmaceuticals and specialty pharmaceuticals.
AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products, and venous products. More information is available at www.angiodynamics.com.
Proquest Identifier: 1131089911
* To access this Proquest article the user must create an account. |
|
Return to ToC |
EKOS to be Honored as Tibbetts Award Winner
Business Wire. New York: Sep 26, 2006. pg. n/a
EKOS Corporation of Bothell, Washington has been selected as one of the winners of the 2006 Tibbetts Awards. Doug Hansmann will receive the award on Sept. 26 at the Wyndham Washington, located at 1400 M Street NW in Washington, D.C.
Named for Roland Tibbetts--the person acknowledged as the father of the Small Business Innovation Research (SBIR) program--these prestigious, national awards are made annually to those small firms, projects, organizations and individuals judged to exemplify the very best in SBIR achievement. EKOS is one of 55 companies in the U.S. to receive this award. EKOS was select from over 4,000 companies that receive contract and grants under the SBIR Program each year.
EKOS Corporation has developed ultrasound enhanced drug delivery catheters that are small enough to travel through blood vessels and quickly dissolve dangerous clots that can develop in the upper extremity, legs and pelvis.
Coined Ultrasound Accelerated Thrombolysis (USAT), the technology unlocks the clot making it more available to drugs called lytics that liquefy the clot and restore blood flow. Once the clot is removed, the physician can determine the cause of the blood clot and take corrective action.
The EndoWave catheter is commercially available for treatment of blood clots in peripheral arteries, veins and grafts. The NeuroWave catheter has shown early promise in the treatment of stroke causing clots in the brain and is currently part of a National Institute of Health stroke trial.
The complete list of winners can be found at tibbettsawards.org.
Proquest Identifier:
1136143421
* To access this Proquest article the user must create an account. |
|
Return to ToC |
Business & Finance; Kensey Nash Q4 and FY 2006 results at high end of estimates
Cardiovascular Week. Atlanta: Sep 18, 2006. pg. 41
2006 SEP 18 - (NewsRx.com) -- Kensey Nash Corp. (KNSY) reported results for its fourth quarter of fiscal year 2006, which were at the high end of previously announced estimates. Fourth-quarter pro forma diluted earnings of $0.26 per share, excluding facility transition charges and equity compensation expense, were at the high end of previously announced expectations of $0.24-0.26 per share and represented 22% sequential growth over pro forma earnings per share for the March 2006 quarter.
Reported diluted earnings per share for the quarter were $0.21. Total revenues of $18.4 million increased 17% sequentially over the March 2006 quarter of $15.7 million and 13% over the prior-year comparable quarter of $16.3 million, and exceeded the company's guidance range of $16.8-17.6 million. Total net sales were stronger than expected and increased 16% year over year and 25% sequentially to $12.5 million compared to $10.7 million in the prior-year period and $10.0 million in the March 2006 quarter.
Royalty income increased 6%, to $5.9 million, from $5.6 million in the prior-year comparable period. Royalty income included $5.1 million in Angio-Seal royalties, up 3% from the comparable quarter of the prior fiscal year, and $806,000 in royalties from Orthovita (VITA), up 30% from the prior-year period. Pro forma gross margin was 54% in the fourth quarter 2006, down sequentially from 58% in the March quarter. This unfavorable margin trend, despite the sequential increase in sales, relates to obsolescence charges for process and raw material changes in 1 specific collagen product as well as unfavorable manufacturing variances related to production start-up of the 3 new products within the endovascular product line, both of which totaled approximately $490,000.
During the fourth quarter ended June 30, 2006 and 2005, the company recognized facility transition costs of $605,000 and $813,000, respectively. These charges consisted of $390,000 in accelerated depreciation charges and $215,000 in moving costs in the fourth quarter of fiscal 2006 and $813,000 in accelerated depreciation charges in the fourth quarter of fiscal 2005. In addition, total equity compensation expense of $642,000 was recorded in the current quarter, as is now required by the applicable accounting rules. On a pro forma basis, excluding these charges, earnings per share were $0.26 compared to $0.33 in the prior year comparable period.
Net sales of orthopedic products, which were $6.1 million in the fourth quarter of fiscal 2006, increased 32% over the prior-year fourth quarter and 9% sequentially. Orthopedic sales included $4.4 million of sales to Arthrex, Inc., representing a 39% increase over the March quarter and a 28% increase over the prior-year comparable quarter. These increases were partially related to new product introductions by Arthrex as well as solid growth in their existing product lines.
Net sales of cardiology products during the quarter were $5.0 million, a 14% increase from the prior year and a 52% increase sequentially over the third quarter of fiscal 2006. These increases related to the timing of shipments of the Angio-Seal collagen plug and anchor components to St. Jude Medical, as third-quarter sales had been down compared to the sequential and year-over-year periods.
Net sales of endovascular products were $432,000 during the quarter, and included $366,000 of U.S. sales, a 181% sequential increase over the March quarter. This increase was the result of the successful market launch of the company's recently U.S. Food & Drug Administration-cleared QuickCat Extraction Catheter.
In Europe, the QuickCat device received CE Mark approval in the June 2006 quarter and the product was launched in August 2006. The company is awaiting CE Mark approval for the ThromCat device. The company is also seeking CE Mark approval for the TriActiv ProGuard System, a new version of the TriActiv System that incorporates a Local Flush and eXtraction (FX) technology designed for use in branched arteries, during carotid stenting procedures. The company anticipates a launch of the ProGuard System for use in carotid arteries in the second half of the current fiscal year. The carotid market represents an important annual market opportunity of over 500,000 people who suffer from carotid artery disease.
"We are very pleased with the results of the fourth quarter," stated Joseph Kaufmann, president and CEO of Kensey Nash Corp. "Not only did the biomaterials business show 23% sequential growth over the March quarter and 16% year-over-year growth, but sales of our endovascular products, specifically the newly launched QuickCat device, were strong. We are excited about the initial QuickCat success along with the recent FX launch and the upcoming ThromCat introduction in the U.S. and Europe. Both our biomaterials and endovascular platforms are well-positioned for growth in fiscal 2007."
Proquest Identifier:
1126057261
* To access this Proquest article the user must create an account. |
|
Return to ToC |
OmniSonics Appoints Dr. Elvira Lang as Vice President and Chief Medical Officer
PR Newswire. New York: Sep 28, 2006. pg. n/a
Rhonda Rosenbaum
OmniSonics Medical Technologies, Inc. 978-657-9980, X348 rrosenbaum@omnisonics.com
WILMINGTON, Mass., Sept. 28 /PRNewswire/ -- OmniSonics MedicalTechnologies, Inc., a developer of advanced medical devices, has announced theappointment of Dr. Elvira V. Lang to the position of Vice President and ChiefMedical Officer.
Dr. Lang most recently served as Chief of Vascular/Interventional Radiology at the Beth Israel Deaconess Medical Center (BIDMC), Boston for the past eight years. In 1999 she was appointed Associate Professor of Radiology at Harvard Medical School. Dr. Lang completed fellowships at the University of California, San Diego, and the Mallinckrodt Institute of Radiology in St. Louis, then joined the faculty at Stanford University, heading the interventional department at the VA Medical Center in Palo Alto for five years. She then directed the Interventional Radiology unit at the University of Iowa Hospitals and Clinics, Iowa, where she also implemented a commercially successful stent development lab before joining the BIDMC as Section Chief in 1998. Dr. Lang is also known for her pioneering NIH-funded studies that suggest the effectiveness of hypnotherapy in controlling pain during surgery.
With extensive experience in all aspects of interventional radiology, Dr. Lang has special experience in revascularization of severe advanced ischemia, sharp recanalization of chronic venous occlusions, pulmonary suction thrombectomy, percutaneous endoscopic methods, and production of custom devices.
Dr. Lang received her M.D. degree, magna cum laude, from the University of Heidelberg School of Medicine where she also served on the faculty.
"We are honored and excited to welcome Dr. Lang to OmniSonics. With her impressive, extensive background, she will play a pivotal role in the development and commercialization of our products for vascular occlusive disease," said Richard Ganz, President and CEO.
"I am pleased to be a part of the OmniSonics team and its emerging OmniWave Technology platform. I look forward to working with OmniSonics to continue to build the company into a successful medical device enterprise," said Dr. Lang.
About OmniSonics Medical Technologies, Inc.
OmniSonics Medical Technologies, Inc., based in Wilmington, MA, is a venture-backed medical device company focused on developing breakthrough products for the treatment of vascular occlusive disease.
About the OmniWave Technology Platform
The Company's first product, the Resolution(R) System, is based on the Company's patented OmniWave(TM) Technology, the first technology to enable the delivery of low-power acoustic energy around the active length of a small diameter wire in a diseased blood vessel. The Resolution System with OmniWave technology is designed to rapidly reduce occlusive materials to red blood cell size particles without harming healthy tissue.
The Resolution System is cleared in the U.S. for the treatment of thrombosed hemodialysis access grafts. Clearance for use in peripheral vascular disease is expected in 2007. Additional clinical trials are planned for other indications.
Proquest Identifier:
1136638231
* To access this Proquest article the user must create an account. |
|
Return to ToC |
Possis Medical, Inc., to Present at the UBS Global Life Sciences Conference
Business Wire. New York: Sep 25, 2006. pg. n/a
Possis Medical, Inc. (NASDAQ:POSS), today announced that it is participating in the UBS Global Life Sciences Conference at The Grand Hyatt Hotel in New York on Wednesday, September 27, 2006. Jules Fisher, vice president of finance and CFO, and John Riles, director of global marketing and new business development, are scheduled to present a company overview and discuss Possis' pioneering medical technologies to conference attendees at 7:30 a.m. ET.
A live Webcast of the presentation will be available at 7:30 a.m. ET on Wednesday, September 27, at www.possis.com under the "Investors" tab. A replay will be available beginning approximately three hours after the live presentation at the same address until October 28, 2006.
Proquest Identifier:
1136147171
* To access this Proquest article the user must create an account. |
|
Return to ToC |
Possis gets clearance for occlusion system to manage blood flow in peripheral interventions
Hematology Week via NewsRx.com & NewsRx.net
September 18, 2006
Possis Medical, Inc. (POSS) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its GuardDog Occlusion System for use during the treatment of peripheral vascular disease.
The GuardDog System enables physicians to manage local blood flow while employing interventional techniques and devices to treat vascular disease.
The GuardDog Occlusion System is the first guidewire-based occlusion device designed and marketed with the specific challenges of the peripheral vasculature in mind. It features a 0.035" diameter guidewire, preferred for peripheral interventions, and a soft, compliant, CO2-filled balloon providing quick inflation and deflation.
Designed to facilitate delivery of over-the-wire interventional tools, the GuardDog System can be delivered through 0.038" diagnostic catheters to the treatment site. The GuardDog System can be inflated, deflated and positioned up to three times during a single procedure, improving efficiencies in both routine and complicated procedures. These GuardDog System features enable physicians to manage blood flow and achieve desired occlusion in peripheral vessels 3-6mm in size.
Possis is completing necessary production requirements in preparation for market evaluations at select medical sites to support full U.S. market release of the GuardDOG System by the end of the calendar year. Anticipated revenue from the GuardDOG System is reflected in the company's current guidance for fiscal 2007.
In addition to the 0.0035" GuardDog device, Possis is also developing a 0.014" version of the device. The company expects 510(k) clearance for the 0.014" version later in fiscal 2007.
* To access this Lexis-Nexis article the user must create an account. |
|
Return to ToC |
Possis Medical Inc. Receives FDA Approval for Fetch(TM) Aspiration Catheter
Business Wire. New York: Oct 9, 2006. pg. n/a
JULES L. FISHER, Vice President, Finance and Chief Financial Officer, 763-450-8011 jules.fisher@possis.com
Possis Medical, Inc. (NASDAQ--NMS:POSS) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Fetch Aspiration Catheter. Utilizing catheter technology from the company's premier AngioJet(R) Rheolytic Thrombectomy System, the Fetch Aspiration Catheter offers physicians another alternative for the aspiration of small, fresh blood clots (thrombus) and other embolic debris from arteries.
"Our goal is to offer physicians a full range of solutions for thrombus removal," said Robert Dutcher, chairman, president and CEO of Possis Medical. "Our AngioJet Thrombectomy System continues to grow as the market leader and gold standard for thrombectomy in peripheral, coronary and dialysis access interventions. Although manual aspiration catheters such as the Fetch catheter offer much less thrombus removal capability than the AngioJet Thrombectomy System, the addition of the Fetch Aspiration Catheter provides physicians with a quick and simple means to aspirate small amounts of fresh thrombus and embolic debris from small coronary arteries.
"As the recognized leader in thrombus management, the addition of the Fetch Aspiration Catheter to our product line further enhances our position as an increasingly valuable partner to our 1,800 current customers who deal with thrombus," said Dutcher.
According to Possis, the rapid exchange Fetch Aspiration Catheter uses an industry-standard syringe as its aspiration source. To provide the flexibility and handling that interventional procedures require, Fetch features an advanced braided shaft design used in other AngioJet thrombectomy catheters marketed by Possis. Additionally, the Fetch catheter is 0.014" guidewire and 6F guide catheter compatible.
"Our proprietary convex tip design, combined with a small outer diameter and hydrophilic coating, minimizes vessel trauma and enhances deliverability. In-house testing showed that the Fetch catheter often outperforms other currently available aspiration devices in the key areas of trackability, contrast injection and aspiration rate. Fetch is a valuable addition to our expanding range of thrombus management and broader endovascular therapies," said Dutcher.
Possis will market the Fetch Aspiration Catheter in the Unites States through the company's sales organization and internationally through an established network of Possis distributors. Anticipated revenue from Fetch catheter sales is reflected in the company's current guidance.
Proquest Identifier:
1142701031
* To access this Proquest article the user must create an account. |
|
Return to ToC |
Endovascular treatment of steno-occlusions of the infrarenal abdominal aorta.***
Radiol Med (Torino). 2006 Oct 11; [Epub ahead of print]
Lagana D,
Carrafiello G,
Mangini M,
Lumia D,
Caronno R,
Castelli P,
Cuffari S,
Fugazzola C.
Vascular and Interventional Radiology, Department of Radiology, , University of Insubria, Viale Borri 57, I-21100, Varese, Italy, donlaga@gmail.com.
PURPOSE.: Our aim is to report our experience in the endovascular treatment of steno-occlusions of the infrarenal abdominal aorta. MATERIALS AND METHODS.: We selected 19 patients (mean age 66.3 years, range 45-80): five with complete occlusion of the infrarenal aorta and both common iliac arteries (CIAs), four of which were associated with occlusion of the external iliac arteries (EIAs); three with complete occlusion and three with severe stenosis of the distal aorta with occlusion or stenosis of the CIAs and EIAs; and eight with focal severe stenosis of the infrarenal aorta. All patients were treated with direct stenting. RESULTS.: Immediate technical success was 94.7% (18/19 cases). We observed two cases of distal embolism treated with thrombolysis, one case of mild renal failure and one case of transient angina abdominis. During the follow-up (mean 19.6 months; range 6-48), 2/18 (11.1%) occlusions of an iliac stent occurred 1 and 3 months after the procedure (treated with local intra-arterial thrombolysis). The primary patency rate was 88.8% and the secondary patency rate was 100%. CONCLUSIONS.: Direct stenting is a feasible and safe option for the treatment of infrarenal abdominal aortic steno-occlusions, especially in patients at high surgical risk, with good early and late clinical results.
PreMedline Identifier:
17021687
***To access this PubMed use the PreMedline Identifier in the PubMed search field. |
|
Return to ToC |
| |
Please click here if you wish to return to the Table of Contents listing the most recent abstract database additions.
If you wish to know more about our MedIntelliBase Custom Email Alert service, please complete our request form or contact us directly for assistance. Our contact information is noted below.
Thank you for your interest in learning what our services can do to empower you -
The Next Phase® Inc. - Medical Technology Consultancy & Publishing
Redmond, WA, USA
Website - www.MedIntelliBase.com
|
|
